Leukaemia

Stamp of approval
#Chemotherapy #European Commission #Leukaemia #Oncology #Otsuka

European Commission approves oral treatment for leukaemia

The European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. INAQOVI, developed by Otsuka Pharmaceutical and Astex Pharmaceuticals, is the first oral hypomethylating agent to be licensed… Read More

#News #Regulatory

European Commission
#Chemotherapy #European Commission #Jazz Pharmaceuticals #Leukaemia #Paediatrics

EC approves Erwinia-derived asparaginase for leukaemia

The European Commission (EC) has granted marketing authorisation for Jazz Pharmaceuticals’ Enrylaze as part of a multi-agent regimen for acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). The treatment is approved in adult and paediatric patients who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. Enrylaze, approved as Rylaze… Read More

#News #Regulatory

CAR-T therapy
#Beam Therapeutics #Cancer research #CAR-T #Clinical trial #Leukaemia #Oncology #T cell activation

First base editing therapeutic for T-ALL/T-LL enters trials

The first quadruplex-edited, allogeneic CAR-T cell therapy candidate has entered clinical trials in the US. The first patient has been treated with Beam Therapeutics’ BEAM-201 as part of a Phase I/II clinical study for the treatment of relapsed/refractory T-cell acute lymphoblastic leukaemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL). Read More

#Cancer Research #News

FDA
#Acute Myeloid Leukaemia #Daiichi Sankyo #FDA #Haematology #Leukaemia

FDA approves quizartinib for acute myeloid leukaemia

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. It is approved with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following… Read More

#News #Regulatory

Leukaemia
#Blood cancer #Cancer research #CHMP #EMA #European Commission #Jazz Pharmaceuticals #Leukaemia #Oncology

EU positive opinion for acute lymphoblastic leukaemia drug

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorisation of JZP458 (a recombinant Erwinia asparaginase or crisantaspase). It has been recommended for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic… Read More

#News #Regulatory

Leukaemia
#Leukaemia #National Institute for Health and Care Excellence (NICE) #Regulatory #UK

UK regulator approves ‘significant advance’ in CLL treatment

The National Institute for Health and Care Excellence (NICE) has approved a combination of Imbruvica (ibrutinib) and venetoclax for all untreated chronic lymphocytic leukaemia (CLL) patients in England. The oral, fixed-duration combination treatment for adult CLL patients has been approved as first-line therapy and has been shown to be more… Read More

#News #Regulatory

Scientist in laboratory
#Antibodies #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Janssen #Leukaemia #Myeloma #Oncology

New trial data revealed in potential myeloma and leukaemia treatments

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase… Read More

#Cancer Research #News

#Acute Myeloid Leukaemia #Blood cancer #Cancer research #Investment #Leukaemia #Plecoid

Pleco Therapeutics raises €17.3m to progress leukaemia drug

Pleco Therapeutics BV has raised €17.3 million in its Series A financing round, which will be used to complete the development of its Plecoid Product, PTX-061, to improve the effectiveness of chemotherapy in patients with acute myeloid leukaemia (AML). The investments include €3.6 million committed by Oost NL and a… Read More

#News

Chronic myeloid leukaemia
#Cancer research #European Commission #Leukaemia #Novartis #Orphan drugs #Scemblix #STAMP inhibitor

European Commission approval for chronic myeloid leukaemia drug

The European Commission (EC) has approved orphan drug Scemblix (asciminib), providing a new treatment option for patients who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). It is approved to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase who have been previously treated with two or more… Read More

#Cancer Research #News

Acute lymphoblastic leukemia
#Leukaemia

Poster: Advancing leukaemia research with magnetic levitation

This poster by Levitas Bio provides a useful guide for leukaemia researchers wanting to use scRNAseq and analysis to uncover new data points. Download the Poster to discover more about: scRNAseq and analysis with enriched, purified cells leads to better data, often uncovering data… Read More

#News

#Clinical trials #Leukaemia #Oncology

Nurix expands protein degrader into CLL   

Biopharmaceutical company Nurix Therapeutics has initiated the first of several potential Phase 1b expansion cohorts in its ongoing Phase 1 trial of its lead drug candidate targeting relapsed or refractory B-cell malignancies  The company’s lead candidate, NX-2127, is an orally administered degrader of Bruton’s tyrosine kinase (BTK)… Read More

#News